Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day
Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for investors and analysts today from 11:30 a.m. to 4:30 p.m. ET in New York City.
Pain management specialists will present data from two Phase 2 studies of NKTR-181, the company's novel mu-opioid analgesic molecule. New topline clinical data will be presented from an ongoing investigator-sponsored Phase 2 study of Nektar's proprietary cancer drug candidate, NKTR-102, in patients with Avastin-resistant high-grade glioma. The company will also present new receptor-based research for NKTR-192, the company's novel analgesic molecule for acute pain, which is currently in Phase 1 development. Noted clinical experts in the fields of pain and oncology will participate in two separate panel discussions on current treatment practices and share their perspectives on the medical need for new treatment options.
Also, for the first time, the company will provide details for two new drug candidates including a peripherally-acting kappa agonist for visceral pain, and a dual-receptor agonist/antagonist molecule for neuropathic pain, both of which were created using the company's advanced polymer conjugate discovery platform. In addition, new preclinical data will be discussed for NKTR-214,